Differential effects of therapeutic anti-α4β7 blockade on homing of leukocyte subsets to the inflamed gut with special focus on effector and regulatory T cells
The inhibition of leukocyte migration from the blood stream to the intestine with the integrin antibody vedolizumab is a new column of the treatment of inflammatory bowel diseases.
Little is known about the impact of vedolizumab on different leukocyte subsets and the dose-response relationship of the drug.
We hypothesize that the targets of vedolizumab differ at high vs. low serum concentrations, which might result in differential efficacy profiles.